"Dutch Ophthalmic Research Center (DORC) is a world-leading retinal surgical instrument developer. Even so, CEO Pierre Billardon recognizes the company has a fair percentage of US market share to obtain.
To take the private equity-backed company through its next growth phase – the goal is to double its equity in three to five years – Pierre listened to DORC’s surgeon customers, strengthened the company’s team, and improved DORC’s internal and external communication.
While innovation remains a key driver for DORC, Pierre remains focused on developing practical solutions. One key example: DORC’s disposable flat vitrectomy lens, a favorite device of host Firas Rahhal, MD.
In this episode, Dr. Rahhal speaks with Pierre about the technology behind TissueBlue, the only Food and Drug Administration-approved selective stain for the internal limiting membrane (ILM), and why it’s superior to using indocyanine green off-label for ILM staining.
You’ll also discover:
- How Pierre’s success at HumanOptics, manufacturer of the CustomFlex artificial iris, has informed his position at DORC. CustomFlex is the first ophthalmic device to receive FDA Breakthrough Device designation.
- The engineering behind the EVA phacoemulsification/vitrectomy system and how it brings LED “light to the eye.”
- How Pierre plans to obtain and maintain market share in a competitive landscape and his vision for the future.
- Why he considers his current leadership role the “job of his dreams.”
WATCH VIDEO VERSION OF THE PODCAST BELOW
CLICK TO LISTEN NOW (link to The Ophthalmology Innovation Summit (OIS) website)